CMS has published updated guidance for billing the cell gene therapy drug, Encelto™. The guidance pertains to Ambulatory surgical centers (ASCs) and hospital outpatient departments, effective for claims with dates of service on or after October 1, 2025. In the article, CMS provides modifiers and fractionated units billing guidance.

Read the August 20, 2026 MLN Connects newsletter for complete details.